Abstract:To the Editor: We read with interest the article by Riddle and co-authors on the use of topical anesthesia for penetrating keratoplasty. Although topical anesthesia is extensively used in cataract surgeries, trabeculectomy, and even pars plana vitrectomy, all these procedures involve the use of instrumentation in a ‘‘closed globe’’ situation. Eye position and movement can be controlled to a reasonable extent even if the patient moves. The situation is different during an open-sky surgery such as penetrating keratoplasty. Even if topical medications can provide adequate anesthesia, they can not provide akinesia. An attempt to hold the globe using instruments can result in unnecessary external pressure, which may cause extrusion of intraocular contents, as mentioned by the authors. We are also not sure of the effects of the preservatives present in topical anesthetics, when they enter the intraocular milieu through the perforation. Apart from ocular movements, the patient may inadvertently squeeze the eyelids, and this can result in even more serious complications. Even in eyes with a corneal perforation, it would be possible, and is possibly safer, to first give a lid block with the eye patched. We are of the opinion that only in very exceptional circumstances should topical anesthesia be considered, and even in those situations, it may be prudent to use parabulbar/subtenon anesthesia once the graft has been anchored with cardinal sutures, restoring the tectonic integrity of the globe. This would provide pain relief and increase the safety of the subsequent steps of surgery. Although we appreciate the efforts of the authors to salvage eyes with a perforation in patients with multiple systemic problems, we are unable to understand the use of this desperate measure in eyes with no perforation. In the article, the authors presented the success rate of completing the surgical procedure using topical anesthesia; however, the pain experienced was only crudely assessed. The visual outcome, the amount of astigmatism, specular studies of the graft, and the visual acuity after keratoplasty were not recorded. We agree that these measures may be secondary outcome measures in eyes with perforated corneal ulcers, where the primary aim of surgery is to restore globe integrity. However, the reporting of such data would be necessary to support the authors’ recommendation that topical anesthesia be considered for routine penetrating keratoplasties performed by experienced surgeons.

Identification of novel selective TRPV3 antagonists based on virtual screening, molecular docking and bioassay

Rational Design and Validation of a Vanilloid-Sensitive TRPV2 Ion Channel.

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

Exploring Functional Roles of TRPV1 Intracellular Domains with Unstructured Peptide-Insertion Screening.

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Structural Pharmacology of TRPV4 Antagonists

Progress in the development of TRPV1 small-molecule antagonists: Novel Strategies for pain management

Structural Basis of TRPV3 Inhibition by an Antagonist.

Penetrating keratoplasty using topical anesthesia.

Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Novel marine natural products as effective TRPV1 channel blockers

Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists

Discovery of N -(1,4-Benzoxazin-3-one) urea analogs as Mode-Selective TRPV1 antagonists

TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site